Insmed (INSM) Cost of Revenue (2018 - 2026)

Insmed's Cost of Revenue history runs 9 years deep, the most recent figure standing at $47.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 122.86% year-over-year to $47.4 million in Q1 2026; TTM through Mar 2026 was $149.1 million, a 66.45% increase from a year earlier, with the FY2025 full-year figure at $122.9 million, up 43.38% from the prior year.
• Cost of Revenue climbed to $47.4 million in Q1 2026 per INSM's latest filing, from $44.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $47.4 million in Q1 2026 and bottomed at $12.2 million in Q1 2022.
• The 5-year median for Cost of Revenue is $18.4 million (2023), against an average of $22.2 million.
• Across the five-year window, Cost of Revenue decreased 1.65% in 2022 and soared 122.86% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $13.1 million in 2022, then jumped by 41.12% to $18.4 million in 2023, then jumped by 41.79% to $26.2 million in 2024, then surged by 69.09% to $44.2 million in 2025, then increased by 7.24% to $47.4 million in 2026.
• Per Business Quant, the three latest INSM Cost of Revenue figures stand at $47.4 million (Q1 2026), $44.2 million (Q4 2025), and $29.4 million (Q3 2025).